The Alzheimer disease (AD) community was unanimous in welcoming the favorable results of Clarity AD,1 an 18-month phase 3 randomized clinical trial of lecanemab in early AD (defined as mild cognitive impairment or mild dementia due to AD). For the first time, an antiamyloid immunotherapy showed an indisputable clinical benefit. Eventually, lecanemab received accelerated approval by the US Food and Drug Administration.